期刊文献+

六元并五元环母核类EGFR酪氨酸激酶抑制剂的研究进展 被引量:2

Research Progress on Five-and-six-membered Heterocyclic EGFR Protein Receptor Tyrosine Kinase Inhibitors
下载PDF
导出
摘要 EGFR抑制剂是抗肿瘤药物研究的热点,文章就近年来新合成的六元并五元环母核类EGFR酪氨酸激酶抑制剂进行综述总结,重点关注国内外已报道的药物骨架结构,简要论述一些抑制剂的结构以及构效关系研究,希望能为EGFR抑制剂后续的研发提供启示和参考。 Since the EGFR inhibitor has become one of the research hotspots in the development of anti-tumor drugs, the paper overviews various kinds of the newly synthesized EGFR inhibitors, and focuses on skeletons of the five-member ring fused with six-member ring, reported by world famous pharmaceutical companies and organizations, furthermore, briefly comments on the structure-activity relationships of some inhibitors, in order to make sense in the future design and research of EGFR inhibitors.
出处 《广东化工》 CAS 2017年第2期63-65,76,共4页 Guangdong Chemical Industry
关键词 表皮生长因子受体 酪氨酸激酶 六元并五元环 epidermalgrowth factorreceptor(EGFR) Tyrosinekinase five-and-six-memberedheterocyclic
  • 引文网络
  • 相关文献

参考文献1

二级参考文献36

  • 1吴一龙.肺癌分子靶向治疗的个体化[J].循证医学,2004,4(2):67-68. 被引量:9
  • 2Zhou H, Kim YS, Peletier A, et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR and HER2-overexpessing breast cancer cell line proliferation, radiosensitization, and resistance [ J ]. Int J Radiat Oncol Biol Phys ,2004,58(2):344- 352.
  • 3Smaill JB,Hollis HD,Zhou H, et al. Tyrosine kinase inhibitors. 18.6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor[J]. J Med Chem ,2001,44(3) :429 - 440.
  • 4David WF, Alexander JB, William AD, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor[J]. Proc Natl Acad Sci USA,1998,95(9) : 12022 - 12027.
  • 5Tsou HR, Mamuya N, Johnson BD, et al. 6-substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity[J]. J Med Chem .2001.44(17) :2719-2734
  • 6Liechti C,Sequin U, Bold G, et al. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor [ J ]. Eur J Med Chem ,2004,39( 1 ) : 11 - 26.
  • 7Dancey J. Epidermal growth factor receptor inhibitors in clinical development[J]. Int J Radiat Oncol Biol Phys ,2004,58(3) : 1003 -1007.
  • 8Michael AG, Bock C, Ferguson LR. Evidence for epidermal growth factor receptorenhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033 [J].Anticancer Drugs ,2001,12(7) :683 - 690.
  • 9David WF, James MNe, Veronika S, et al. Biochemical and antiproliferative properties of 4-[Ar(alk) ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor[ J ]. Biol Pharmacol, 1997,54( 8 ) :877 - 887.
  • 10Alan EW, Guy SP, Woodburn JR, et al. ZD1839 (lressa) : an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy [ J ]. Cancer Res, 2002,62(15) : 5749 - 5754.

共引文献30

同被引文献16

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部